#GlobalNews: “U.S. pharma company raises price of generic diarrhea drug by 400% – National”


Hikma Pharmaceuticals Plc’s U.S. subsidiary has raised the price of a common diarrhea drug by more than 400 percent and is charging more for five other medicines as well, the Financial Times reported on Sunday.

West-Ward Pharmaceuticals, the U.S. division of London-listed Hikma, increased the prices at the start of August by between 75 percent and 430 percent, for a mean of 237 percent, according to figures seen by the Financial Times.

In the United States, generic drugmakers such as Hikma are able to dictate prices of their products that have a monopoly or face little competition, the FT said.

RELATED: ‘Pharma bro’ Martin Shkreli convicted of securities fraud

Among the six drugs, West-Ward is either the only U.S. supplier or one of two manufacturers.

The average wholesale price of a 60 ml bottle of liquid Atropine-Diphenoxylate, a common diarrhea drug also known as Lomotil, went from about $16 a bottle to $84, the FT reported.

Brian Hoffmann, president of U.S. generics at West-Ward, said the prices of 94 percent of the group’s copycat medicine portfolio had either fallen or stayed the same in 2017, and that they had fallen overall this year.

Note: “Previously Published on: 20 August 2017 | 9:12 pm, as ‘U.S. pharma company raises price of generic diarrhea drug by 400% – National’ on GLOBALNEWS CANADA. Here is a source link for the Article’s Image(s) and Content”.

Global News Canada

Copyright © 2017 Global News, a division of Corus Entertainment Inc. Corus News. All rights reserved. Distributed by PressOcean Global Media (pressocean.com). Contact the copyright holder directly for corrections — or for permission to republish or make other authorized use of this material... Articles and commentaries that identify PressOcean.com as the publisher are produced or commissioned by PressOcean. To address comments or complaints, please Contact us.


No comments!

There are no comments yet, but you can be first to comment this article.

Leave reply

Leave a Reply, an Opinion or a Comment: